Subject(s)
Pseudoxanthoma Elasticum/diagnosis , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Ductal, Breast/radiotherapy , Carcinoma, Ductal, Breast/surgery , Combined Modality Therapy , Elastic Tissue/ultrastructure , Female , Glycosaminoglycans/analysis , Humans , Middle Aged , Pseudoxanthoma Elasticum/metabolism , Pseudoxanthoma Elasticum/pathology , Staining and LabelingABSTRACT
No disponible
No disponible
Subject(s)
Humans , Adult , Female , Melkersson-Rosenthal SyndromeABSTRACT
We observed a 73-year-old man with necrobiotic xanthogranuloma (NXG) on the eyelids and concurrent multiple myeloma. The treatment was surgery followed by administration of melphalan. No relapse was seen in 19 months of follow-up. We consider that surgical removal of xanthogranuloma is an advisable rapid treatment that involves fewer side-effects than other treatments.
Subject(s)
Granuloma Annulare/pathology , Multiple Myeloma/pathology , Xanthomatosis/pathology , Aged , Biopsy, Needle , Blood Chemical Analysis , Follow-Up Studies , Granuloma Annulare/complications , Granuloma Annulare/drug therapy , Humans , Immunohistochemistry , Male , Melphalan/therapeutic use , Multiple Myeloma/complications , Multiple Myeloma/drug therapy , Rare Diseases , Risk Assessment , Treatment Outcome , Xanthomatosis/complications , Xanthomatosis/drug therapyABSTRACT
Forty patients with pityriasis versicolor, fluorescence of involved areas under Wood's light, and positive microscopic identification of Malassezia furfur were randomly assigned to treatment with either oral itraconazole (200 mg once daily for five consecutive days) or 2.5% selenium sulfide shampoo (once daily application for seven days). Each treatment group consisted of 20 patients. On assessment three weeks after the end of treatment, all patients given itraconazole showed a response: 17 were healed, and three had mild residual lesions. Likewise, all patients in the selenium sulfide group responded to therapy: 16 were healed, and four had mild residual lesions. Tolerability, acceptability, and compliance were excellent with itraconazole. All 20 patients given the drug stated a preference for oral treatment. In the selenium sulfide group, five patients (25%) had adverse reactions attributable to the medication; one of these patients experienced an irritation severe enough to warrant the discontinuation of treatment on the third day. Ten patients in this group stated a preference for oral treatment.
